Study wrapper · #930
GIPR:GCGR co-agonism restores normal weight in obese rodents.
Perez-Tilve D, Zhang F, Zhang Y, et al. Molecular metabolism. 2026.
DOI: 10.1016/j.molmet.2026.102365PubMed: 41997446
Editor's note
This is preclinical rodent research where retatrutide serves as a benchmark comparator to a new GLP-1-sparing co-agonist. It offers a mechanistic signal that weight reduction can occur without GLP-1 activity, potentially reducing gastrointestinal effects, but findings are animal-only and early. Retatrutide is central to the comparison rather than the novel agent tested.
Plain-language abstract
In obese mice and rats, a GIPR/GCGR co-agonist reduced excess body weight comparably to retatrutide, which normalized weight even in mice lacking the GLP-1 receptor.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026